RxDoctor Payments Data

Zoltan Varga

Interventional Cardiology · Russellville, ARNPI 1336645225

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 80.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $5,619 and has fallen 98.5% since, to $85 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AR, where the typical reported total is $7,561.

$6,210in general payments, 2019–2025

Across 103 payments — averaging $60.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$571
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$170
  • Abiomed$132
  • Novartis$39
  • Boston Scientific$35
  • plus $253 from 11 others

What the payments were for

  • Travel & lodging$3,16551%
  • Food & beverage$2,89147%
  • Education$1532%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,210 in reported general payments places this provider in the 40th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$196,712
Medicare patients
662
Services billed
3,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$248,872
FarxigaDapagliflozin Propanediol152$135,396
EntrestoSacubitril/Valsartan145$109,383
XareltoRivaroxaban58$40,520
BrilintaTicagrelor54$33,000
Repatha SureclickEvolocumab25$14,076
Ranolazine ErRanolazine147$12,855
Rosuvastatin Calcium352$4,159
Metoprolol Succinate288$4,099
Nifedipine ErNifedipine131$3,777
ClopidogrelClopidogrel Bisulfate342$3,359
Atorvastatin Calcium297$2,701
Spironolactone387$2,657
Losartan Potassium351$2,640
Isosorbide Mononitrate ErIsosorbide Mononitrate295$2,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$248,872297 claims
AstraZenecaFarxiga, Brilinta$15$168,396206 claims
NovartisEntresto$39$109,383145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →